A Phase I Study of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors

BACKGROUND: Fenretinide is a synthetic retinoid that can induce cytotoxicity by several mechanisms. Achieving effective systemic exposure with oral formulations has been challenging. An intravenous lipid emulsion fenretinide formulation was developed to overcome this barrier. We conducted a study to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Chemother Pharmacol
Hauptverfasser: Thomas, Jacob S., El-Khoueiry, Anthony B., Maurer, Barry J., Groshen, Susan, Pinski, Jacek K., Cobos, Everardo, Gandara, David R., Lenz, Heinz J., Kang, Min H, Reynolds, C. Patrick, Newman, Edward M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2021
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8058950/
https://ncbi.nlm.nih.gov/pubmed/33423090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04224-8
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge